Transition Period and Young Adulthood in Patients with Childhood Onset Growth Hormone Deficiency (COGHD): Impact of Growth Hormone Replacement on Bone Mass and Body Composition

被引:0
作者
Doknic, Mirjana [1 ,2 ]
Stojanovic, Marko [1 ,2 ]
Markovic, Aleksandra [3 ]
机构
[1] Univ Clin Ctr Serbia, Neuroendocrine Dept, Clin Endocrinol Diabet & Metab Dis, Beograd 11000, Serbia
[2] Univ Belgrade, Fac Med, Belgrade 11000, Serbia
[3] Univ Banja Luka, Univ Clin Ctr Republ Srpska, Fac Med, Dept Endocrinol,Internal Med Clin, Banja Luka 78000, Bosnia & Herceg
关键词
transition period; GHD; GH therapy; bone; body composition; GH DEFICIENCY; MINERAL DENSITY; CLINICAL CHARACTERISTICS; SKELETAL-MUSCLE; SINGLE-CENTER; FINAL HEIGHT; THERAPY; ADOLESCENTS; CHILDREN; METABOLISM;
D O I
10.3390/ijms251910313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this review article is to highlight the consequences of COGHD after the end of linear growth on bone mass and body composition and the opposing beneficial effects of continuing GH replacement in the transition period and young adults. The role of growth hormone in the period of late adolescence and young adulthood is well established, mainly in achieving peak bone mass and a favorable body composition, characterized by muscle mass increase and fat mass reduction. Patients with childhood onset growth hormone deficiency (COGHD), after reaching the adult height, have a reduced bone mineral density and muscle mass with increased fat mass compared to healthy controls. Inadequate body composition is a predictor for cardiovascular risk, while low bone mass in early youth hallmarks the risk of osteoporosis and bone fractures in later life. Cessation of growth hormone replacement (GHr) after completion of growth will lead to delayed peak bone mass and unbalanced body composition with increased abdominal fat deposits. According to numerous clinical studies monitoring the effects of GH treatment on the physical and psychological status of patients with persistent GHD after completion of growth, we suggest continuing this treatment between 16 and 25 years of age. It is advised that GHr in the transition period be administered in intermediate doses between those for the pediatric population and those for the adult population. Usual daily GHr doses are between 0.3 and 0.5 mg but need to be individually optimized, with the aim of maintaining IGF-I in the age-specific normal range.
引用
收藏
页数:19
相关论文
共 103 条
  • [21] Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men
    Bravenboer, N
    Holzmann, P
    deBoer, H
    Blok, GJ
    Lips, P
    [J]. BONE, 1996, 18 (06) : 551 - 557
  • [22] Prospective Follow-up of Children with Idiopathic Growth Hormone Deficiency After Termination of Growth Hormone Treatment: Is There Really Need for Treatment at Transition to Adulthood?
    Camtosun, Emine
    Siklar, Zeynep
    Berberoglu, Merih
    [J]. JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2018, 10 (03) : 247 - 255
  • [23] Low bone mineral density in a growth hormone deficient (GHD) adolescent
    Capozzi, Anna
    Della Casa, Silvia
    Altieri, Barbara
    Pontecorvi, Alfredo
    [J]. CLINICAL CASES IN MINERAL AND BONE METABOLISM, 2013, 10 (03) : 203 - 205
  • [24] Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth
    Carroll, PV
    Drake, WM
    Maher, KT
    Metcalfe, K
    Shaw, NJ
    Dunger, DB
    Cheetham, TD
    Camacho-Hübner, C
    Savage, MO
    Monson, JP
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08) : 3890 - 3895
  • [25] Action of GH on skeletal muscle function: molecular and metabolic mechanisms
    Chikani, Viral
    Ho, Ken K. Y.
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2014, 52 (01) : R107 - R123
  • [26] Difficulties in patient management associated with the transition period
    Clayton, PE
    Shalet, SM
    [J]. HORMONE RESEARCH, 2005, 64 : 74 - 75
  • [27] Consensus statement on the management of the GH-treated adolescent in the transition to adult care
    Clayton, PE
    Cuneo, RC
    Juul, A
    Monson, JP
    Shalet, SM
    Tauber, M
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (02) : 165 - 170
  • [28] Growth hormone replacement throughout life: Insights into age-related responses to treatment
    Clayton, Peter
    Gleeson, Helena
    Monson, John
    Popovic, Vera
    Shalet, Stephen M.
    Christiansen, J. Sandahl
    [J]. GROWTH HORMONE & IGF RESEARCH, 2007, 17 (05) : 369 - 382
  • [29] Bone density in post-pubertal adolescent survivors of childhood brain tumors
    Cohen, Laurie E.
    Gordon, Joshua H.
    Popovsky, Erica Y.
    Sainath, Nina N.
    Feldman, Henry A.
    Kieran, Mark W.
    Gordon, Catherine M.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 58 (06) : 959 - 963
  • [30] Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency
    Conway, G. S.
    Szarras-Czapnik, M.
    Racz, K.
    Keller, A.
    Chanson, P.
    Tauber, M.
    Zacharin, M.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 160 (06) : 899 - 907